Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Forum Financial Management LP

Forum Financial Management LP increased its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 0.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 352,784 shares of the medical research company's stock after acquiring an additional 2,411 shares during the quarter. Amgen makes up 1.5% of Forum Financial Management LP's investment portfolio, making the stock its 11th largest position. Forum Financial Management LP owned approximately 0.07% of Amgen worth $91,950,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Centricity Wealth Management LLC bought a new stake in shares of Amgen in the 4th quarter worth $25,000. Ritter Daniher Financial Advisory LLC DE grew its holdings in Amgen by 66.2% during the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock valued at $33,000 after purchasing an additional 51 shares during the period. Synergy Investment Management LLC purchased a new position in shares of Amgen in the fourth quarter valued at about $34,000. Atala Financial Inc bought a new position in Amgen during the fourth quarter valued at approximately $34,000. Finally, Heck Capital Advisors LLC bought a new position in Amgen during the fourth quarter valued at approximately $36,000. Hedge funds and other institutional investors own 76.50% of the company's stock.

Amgen Price Performance

Shares of AMGN traded up $5.14 during mid-day trading on Thursday, reaching $283.54. The company had a trading volume of 2,801,720 shares, compared to its average volume of 2,802,638. The company's 50 day simple moving average is $283.86 and its 200 day simple moving average is $285.50. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The company has a market capitalization of $152.46 billion, a price-to-earnings ratio of 37.56, a P/E/G ratio of 2.63 and a beta of 0.51.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, beating the consensus estimate of $4.18 by $0.72. The company had revenue of $8.15 billion during the quarter, compared to analyst estimates of $8.05 billion. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Amgen's revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.96 EPS. Analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be issued a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.36%. The ex-dividend date is Friday, May 16th. Amgen's payout ratio is 86.86%.

Wall Street Analysts Forecast Growth

AMGN has been the topic of several research analyst reports. Wall Street Zen raised Amgen from a "buy" rating to a "strong-buy" rating in a research note on Sunday, May 18th. Citigroup reissued a "neutral" rating on shares of Amgen in a research report on Wednesday, February 5th. Mizuho raised their target price on Amgen from $235.00 to $280.00 and gave the stock a "neutral" rating in a research note on Wednesday, May 7th. Royal Bank of Canada reduced their price objective on Amgen from $324.00 to $320.00 and set an "outperform" rating for the company in a research note on Friday, May 2nd. Finally, Piper Sandler cut their price target on Amgen from $329.00 to $328.00 and set an "overweight" rating for the company in a research note on Friday, May 16th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $309.22.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.